Anatara Lifesciences announced changes to its management team, including the retirement of Dr. Paul Schober as CEO, transition of Dr. Mel Bridges into a combined CEO /Chairman role as well as the appointment of Dr. Mike West as COO. The company has accepted CEO, Dr. Paul Schober's plans to move to retirement over the next three months as part of a closely managed transition plan, commencing June 27, 2016. Anatara is also announced the appointment of Dr. Michael West as Chief Operating Officer (COO), effective July 1, 2016.

Dr. West has extensive global GMP manufacturing, regulatory and drug launch scale-up expertise, including experience with global drug company SmithKline Beecham (now GSK) in the USA, Alchemia Limited and the Centre for Drug Design & Development at the University of Queensland. Dr. West has served on the Pharmaceutical subcommittee to the Australian Drug Evaluation Committee at the Therapeutic Goods Administration (TGA). Dr. West will report directly to Dr. Bridges and form part of the senior leadership team - also reporting to the board.

Dr. West will assume ownership for key areas of responsibility that have been managed to date by Dr. Schober.